The medicine, developed by a New Haven biotech firm named Alexion, is called Soliris and it's important to note that it genuinely helps many of those who have one of two rare and often fatal blood disorders — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic - uremic syndrome (aHUS). (fortune.com)
(Soliris) A drug approved by the U.S. Food and Drug Administration (FDA) and in Europe to treat paroxysmal nocturnal hemoglobinuria (PNH). (aamds.org)
In the rare, life - threatening disease called paroxysmal nocturnal hemoglobinuria (PNH), patients are stricken with chronic anemia and blood clots, when the oldest part of the immune system — known as complement — turns against its own red blood cells, or erythrocytes. (pennmedicine.org)